ArticleJournal of neuro-oncology2026
Prognostic impact of RANO resect group classification post-chemoradiotherapy in IDH-wildtype glioblastoma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundClassification by the Response Assessment in Neuro-Oncology (RANO) resect group has recently been proposed as a prognostic stratification system for glioblastoma (GBM). However, postoperative T2-weighted/FLAIR (T2W/FLAIR) abnormalities may include edema and surgery-related changes, limiting accurate evaluation of non-contrast-enhancing tumor burden. Therefore, we investigated the prognostic utility of post-chemoradiotherapy (post-CRT) RANO resect classification and T2W/FLAIR volumetric changes in GBM.
methodsWe retrospectively analyzed 105 consecutive patients with GBM who underwent surgical resection followed by CRT. MRI-based volumetric analyses were performed, RANO resect classification was applied, and T2W/FLAIR-based parameters were evaluated.
resultsOnly one patient was classified as postoperative RANO resect Class 1, whereas 10 met Class 1 criteria following CRT. Post-CRT RANO resect classification demonstrated superior prognostic stratification compared with postoperative classification (Classes 1, 2 A, 2B, 3 A, and 3B; progression-free survival: 10, 11, 7.5, 5, and 3 months, respectively; p < 0.001; overall survival [OS]: 32.5, 27, 16, 14, and 15 months, respectively; p < 0.001). Survival outcomes did not differ between Classes 1 and 2 A. Among 49 patients with post-CRT RANO resect Class 1/2A, T2W/FLAIR volume reduction ≥ 80% was independently associated with improved OS (hazard ratio: 0.36, p = 0.013). Patients with either RANO resect Class 1 or ≥ 80% T2W/FLAIR reduction demonstrated significantly improved progression-free survival and OS. Telomerase reverse transcriptase (TERT) promoter wildtype status was independently associated with lower post-CRT T2W/FLAIR volume.
conclusionsPost-CRT RANO resect classification may provide improved prognostic stratification in GBM. Integration of T2W/FLAIR volume reduction may further refine prognostic assessment within non-contrast-enhancing tumors.
Indexed as
Identifiers
42538484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.